2023-10-20T01:00:06+00:00 2022-12-31 350921680 CROWE LLP 575 Market Street Suite 3300 San Francisco CA 941055829 990 2022-01-01 841327507 Allosource ALLO 7208730213 6278 S TROY CIRCLE CENTENNIAL CO 80111 Yan Deng CHIEF FINANCIAL OFFICER 7208730213 2023-10-20 true Yan Deng 999009999 DIANE KIRMACI P01578407 4155761100 2022 2023-04-26 12:10:37Z Dean Elliott 6278 S TROY CIRCLE CENTENNIAL CO 80111 157659866 false X HTTPS://ALLOSOURCE.ORG/ X 1994 IL ALLOSOURCE RESPONSIBLY PROCESSES AND DISTRIBUTES HUMAN DONATED TISSUE THAT ENHANCES AND SAVES LIVES. 6 5 609 5 0 0 8425622 217852 147038805 156687600 374888 790722 53777 -36308 155893092 157659866 347343 273366 0 0 47567679 48821753 0 0 0 102055167 115856436 149970189 164951555 5922903 -7291689 159280859 151465252 54410941 55697683 104869918 95767569 INSPIRED BY THE GIFT OF DONATION FROM OUR COMMUNITIES, ALLOSOURCE RESPONSIBLY PROVIDES INNOVATIVE CELLULAR AND TISSUE ALLOGRAFTS TO ADVANCE PATIENT HEALING. false false 144805662 156651292 PROCESSING AND DISTRIBUTION: WITH THE GIFT OF DONATED TISSUE, ALLOSOURCE PROVIDES INNOVATIVE CELLULAR AND TISSUE ALLOGRAFTS TO ADVANCE PATIENT HEALING. IN 2022, ALLOSOURCE FULFILLED THIS RESPONSIBILITY BY PROCESSING MORE THAN 8,600 DONORS, AND DISTRIBUTED THE TISSUE THROUGHOUT NORTH AMERICA, SOUTH AMERICA, CENTRAL AMERICA, CARIBBEAN, EUROPE, MIDDLE EAST, ASIA AND OCEANIA. MUSCULOSKELETAL AND SOFT TISSUE DONORS PROVIDE AN OPPORTUNITY TO CREATE LIFE-SAVING AND LIFE-ENHANCING SOLUTIONS IN ORTHOPEDIC, SPINE, BURN, AND WOUND PROCEDURES TO HELP RESTORE PATIENT HEALTH AND MOBILITY. ALLOSOURCE IS ACCREDITED BY THE AMERICAN ASSOCIATION OF TISSUE BANKS AND IS REGISTERED WITH THE FDA. 8354325 50000 RESEARCH, EDUCATION, AND TRAINING: ALLOSOURCE IS DEDICATED TO ADVANCING THE USE OF TRANSPLANTABLE ALLOGENEIC CELLS AND TISSUE THROUGH PIONEERING RESEARCH. IN 2022, ALLOSOURCE CONTINUED ITS RESEARCH IN THE AREAS OF PEDIATRIC ORTHOPEDICS AND CELLULAR THERAPIES, EXPANDING THE IMPACT OF DONATION BY FINDING ADDITIONAL USES FOR TISSUE. ALLOSOURCE WORKED WITH THE 501(C)(3) ORGANIZATIONS THAT RECOVER TISSUE TO REDUCE TISSUE CONTAMINATION. WE ALSO PROVIDED EDUCATIONAL OPPORTUNITIES TO OUR PARTNER ORGAN PROCUREMENT ORGANIZATIONS TO HELP THEM INCREASE DONATION RATES IN THEIR RESPECTIVE COMMUNITIES. 223366 223366 CHARITABLE CONTRIBUTION ACTIVITY: IN ALIGNMENT WITH OUR MISSION, ALLOSOURCE PROVIDED GRANTS TO SUPPORT 501(c)(3) ORGANIZATIONS THAT ARE INVOLVED IN ORGAN, EYE, AND TISSUE DONATION, S.T.E.M. EDUCATION, AS WELL AS PATIENT PHYSICAL AND MENTAL HEALING. IN 2022, ALLOSOURCE GAVE GRANTS TO FOUR ORGANIZATIONS TO FURTHER TISSUE DONATION AND TRANSPLANTATION AWARENESS AND PROCESSES, AND MADE CHARITABLE CONTRIBUTIONS TO SEVENTEEN OTHER 501(C)(3) ORGANIZATIONS THROUGH DIRECT AND MATCHING EMPLOYEE FINANCIAL DONATIONS. 153383353 true true false false false false false false false true false false false true false false true false false true false false false false false false true false true true false false false false false false false false false false false false false false true false false false false true 159 0 true 609 true false false false false false false false false false false false false X 6 5 false false false false true true false true false false false true true true true true true true true false CA IL NY X YAN DENG 7208730213 6278 S TROY CIRCLE CENTENNIAL CO 80111 DIANE BROCKMEIER BOARD MEMBER - CHAIR 3.0 X X 0 0 0 JENNIFER PRINZ BOARD MEMBER - TREASURER 3.0 X X 0 0 0 THOMAS A CYCYOTA PRESIDENT, CEO 40.0 X X 825722 0 159225 DR HARRY WILKINS BOARD MEMBER 3.0 X 0 0 0 MARK SIMON BOARD MEMBER 3.0 X 0 0 0 SUZANNE CONRAD BOARD MEMBER 3.0 X 0 0 0 DEAN H ELLIOTT CHIEF OPERATING OFFICER 40.0 X 453550 0 54038 KEVIN L WHITTEN CHIEF COMMERCIAL OFFICER 40.0 X 280235 0 29022 YAN DENG CHIEF FINANCIAL OFFICER 40.0 X 307507 0 20022 ALAN OKERMAN DIRECTOR IT 40.0 X 208834 0 16807 BRIAN R BOBKA VP INTERNATIONAL 40.0 X 255866 0 41768 KENNETH HAMMONS SVP OPERATIONS 40.0 X 266359 0 17612 KIMBERLY MEYER SVP QUALITY & PERFORMANCE EXCELLENCE 40.0 X 231907 0 26999 MICHELLE ZEPPELIN VP HUMAN RESOURCES 40.0 X 227277 0 14565 RAPHAEL DIAZ VP SALES 40.0 X 206277 0 21139 COREY STONE EXECUTIVE DIRECTOR ESSENT BIOLOGICS 40.0 X 238371 0 22203 HANNIS W THOMPSON III MEDICAL DIRECTOR 40.0 X 315467 0 19289 INGA GUREVICH ASSOCIATE MEDICAL DIRECTOR 40.0 X 221894 0 21602 JOHN LAFAKIS AREA MANAGER 40.0 X 222815 0 24661 MATTHEW OZMENT REGIONAL ACCOUNTS MANAGER - PLASTICS 40.0 X 211414 0 19321 4473495 0 508273 121 false true false EUROFINS VRL INC 6933-B REVERE PKWY CENTENNIAL CO 80112 LABRATORY SERVICE 5153907 FEDEX ERS PO BOX 37174 PITTSBURGH PA 152507741 SHIPPING SERVICE 3113290 NORTH AMERICAN SCIENCE ASSOC PO BOX 710970 CINCINATTI OH 45271 BIOASSAY TESTING 1960992 QUICK INTERNATIONAL COURIER 17528 148TH AVE JAMAICA NY 11434 COURIER SERVICE 1650277 MAXTOWN MEDICAL 6295 Maxtown Rd Ste 700 Westerville OH 43082 DISTRIBUTOR COMMISSIONS 1235546 63 0 0 0 0 0 217852 0 217852 TISSUE DISTRIBUTION & PROCESSING 900099 156687600 156687600 0 0 0 0 0 0 156687600 320747 0 0 320747 0 0 0 0 0 0 0 0 0 0 28761 441214 0 0 28761 441214 469975 0 0 469975 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 INCOME (LOSS) FROM JRF 900099 -36308 -36308 0 0 0 0 0 0 0 0 0 0 -36308 157659866 156651292 0 790722 273366 273366 0 0 0 0 0 0 3664730 2961832 702898 0 0 0 0 0 37212896 32039902 5172994 0 626998 495045 131953 0 4450909 3803610 647299 0 2866220 2473799 392421 0 0 0 0 0 612144 306072 306072 0 958004 0 958004 0 0 0 0 0 0 0 0 0 0 0 1722308 1423334 298974 0 412727 0 412727 0 1625642 1254522 371120 0 1143390 850960 292430 0 1226399 1226399 0 0 1852135 1427754 424381 0 732924 635266 97658 0 0 0 0 0 192072 76380 115692 0 641198 577078 64120 0 0 0 0 0 4400297 4153857 246440 0 632215 474161 158054 0 TISSUE PROCESSING COSTS 87106284 87106284 0 0 COST OF DISTRIBUTION 7132596 7132596 0 0 REPAIRS & MAINTENANCE 2717607 2602127 115480 0 LICENSE FEES 1169050 1029260 139790 0 1579444 1059749 519695 0 164951555 153383353 11568202 0 0 0 0 0 204878 54427 15876115 11492170 0 0 18604884 21397355 0 0 0 0 0 0 75940908 72627339 440083 652621 77089959 42798430 36509770 34291529 0 0 3618652 3618652 4762966 4726657 49230 23974 3273373 2580528 159280859 151465252 32395929 34856710 0 0 0 0 15480301 13590659 0 0 0 0 4315869 5290727 0 0 2218842 1959587 54410941 55697683 X 104869918 95767569 0 0 0 0 0 0 0 0 104869918 95767569 159280859 151465252 X -7291689 -1637907 0 0 0 -172753 X false true X true false X 577458 1865159 546574 8425622 217852 11632665 142731120 143684046 134116779 147038805 156687598 724258348 0 0 0 143308578 145549205 134663353 155464427 156905450 735891013 9517130 9710119 10336850 10413568 8296127 48273794 72359586 72292025 67676533 67695468 59123415 339147027 81876716 82002144 78013383 78109036 67419542 387420821 348470192 22267 317511 538846 362398 320747 1561769 0 22267 317511 538846 362398 320747 1561769 0 0 0 0 0 2436070 226679 801575 -41691 -36308 3386325 145766915 146093395 136003774 155785134 157189889 740839107 0.4704 0.4443 0 0.0 X Schedule A, Part III, Line 12 Other Income DESCRIPTION - OTHER INCOME, COLUMN A - 2436070.0, COLUMN B - 226679.0, COLUMN C - 801575.0, COLUMN D - -41691.0, COLUMN E - -36308.0, COLUMN F - 3386325.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 2076368 2076368 48794065 22542653 26251412 11659 11659 0 17536682 12957492 4579190 8671185 7286626 1384559 34291529 DEFERRED COMPENSATION 1682949 CAPITAL LEASE OBLIGATION 0 Operating Lease Liability 276638 1959587 Central America and the Caribbean 0 0 Program Services Tissue Distribution East Asia and the Pacific 0 0 Program Services Tissue Distribution 10237 Europe (Including Iceland and Greenland) 0 0 Program Services Tissue Distribution 21653 Middle East and North Africa 0 0 Program Services Tissue Distribution 6506 North America (Canada & Mexico only) 0 0 Program Services Tissue Distribution 3329 South America 0 0 Program Services Tissue Distribution 0 0 0 0 0 0 41725 0 41725 false false false false false true Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements CENTRAL AMERICA AND THE CARIBBEA; EAST ASIA AND THE PACIFI; EUROPE (INCLUDING ICELAND AND GREENLAND; MIDDLE EAST AND NORTH AFRIC; NORTH AMERICA (CANADA & MEXICO ONLY; SOUTH AMERIC true THE PHOENIX SOCIETY 1835 R W BERENDS DR SW GRAND RAPIDS MI 49519 232062352 501(C)(3) 55000 TO SUPPORT MISSION DONATE LIFE NEW YORK STATE 185 JORDAN RD TROY NY 12180 510430374 501(C)(3) 35000 TO SUPPORT MISSION LIMB PRESERVATION FOUNDATION 1600 BROADWAY ST STE 2400 DENVER CO 80202 841565464 501(C)(3) 25000 TO SUPPORT MISSION CHICAGO SPORTS SUMMIT FOUNDATION ONE WESTBROOK CORPORATE CENTER STE 240 WESTCHESTER IL 60154 371853214 501(C)(3) 5000 TO SUPPORT MISSION IOWA DONOR NETWORK 550 MADISON AVE NORTH LIBERTY IA 52317 421414092 501(C)(3) 5000 TO SUPPORT MISSION MAYO CLINIC 200 FIRST STREET SW Rochester MN 55905 416011702 501(C)(3) 50000 TO SUPPORT MISSION GHANA MAKE A DIFFERENCE PO BOX 55 STAR ID 83669 455615778 501(C)(3) 74773 FMV TISSUE DONATION TO SUPPORT MISSION MERCY SHIP WAREHOUSE 15862 STATE HWY 110 N LINDALE TX 75771 262414132 501(C)(3) 11395 FMV TISSUE DONATION TO SUPPORT MISSION 8 0 Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds. THE CHIEF COMMERCIAL OFFICER COMMUNICATES ON AN ON-GOING BASIS WITH RECIPIENTS OF GRANT FUNDS TO ENSURE THE OBJECTIVES AND GOALS OF THESE PROGRAMS ARE FULFILLED. X X X X X false true false false false false false false false THOMAS A CYCYOTA PRESIDENT, CEO 564027 0 117003 0 144692 0 148073 0 11152 0 984947 0 142554 0 DEAN H ELLIOTT CHIEF OPERATING OFFICER 352748 0 38848 0 61954 0 39573 0 14465 0 507588 0 60353 0 KEVIN L WHITTEN CHIEF COMMERCIAL OFFICER 257108 0 21998 0 1129 0 8434 0 20588 0 309257 0 0 0 YAN DENG CHIEF FINANCIAL OFFICER 278640 0 28246 0 621 0 4194 0 15828 0 327529 0 0 0 BRIAN R BOBKA VP INTERNATIONAL 198327 0 23273 0 34266 0 26007 0 15761 0 297634 0 32600 0 ALAN OKERMAN DIRECTOR IT 185200 0 22638 0 996 0 5441 0 11366 0 225641 0 0 0 RAPHAEL DIAZ VP SALES 189201 0 16764 0 312 0 6464 0 14675 0 227416 0 0 0 KENNETH HAMMONS SVP OPERATIONS 238796 0 26123 0 1440 0 6058 0 11554 0 283971 0 0 0 KIMBERLY MEYER SVP QUALITY & PERFORMANCE EXCELLENCE 207958 0 23679 0 270 0 6600 0 20399 0 258906 0 0 0 MICHELLE ZEPPELIN VP HUMAN RESOURCES 204308 0 22699 0 270 0 6270 0 8295 0 241842 0 0 0 HANNIS W THOMPSON III MEDICAL DIRECTOR 278169 0 33590 0 3708 0 7397 0 11892 0 334756 0 0 0 JOHN LAFAKIS AREA MANAGER 169184 0 46443 0 7188 0 6718 0 17943 0 247476 0 0 0 MATTHEW OZMENT REGIONAL ACCOUNTS MANAGER - PLASTICS 118574 0 86528 0 6312 0 5151 0 14170 0 230735 0 0 0 INGA GUREVICH ASSOCIATE MEDICAL DIRECTOR 210467 0 10239 0 1188 0 6821 0 14781 0 243496 0 0 0 COREY STONE EXECUTIVE DIRECTOR ESSENT BIOLOGICS 206138 0 32077 0 156 0 6632 0 15571 0 260574 0 0 0 Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan The Following individuals participated in a supplemental executive retirement plan in 2022 sponsored by Allosource: Thomas A Cycyota - $ 135,203, Dean Elliot - $36,000, and Brian Bobka - $20,500. The Dollar amount represents the current year Contribution made by AlloSource on behalf of the individuals to the plan in 2022. This information is included in reportable compensation on the form 990, part VII and Schedule J, part II. The Following individuals also participated in a supplemental executive retirement plan in 2022 sponsored by AlloSource: Brian Bobka - $32,600, Dean Elliot - $60,353, Tom Cycyota - $142,554. The Dollar amount represents the current year Distribution made by the plan to the individuals. This information is included in reportable compensation on the form 990, part VII and Schedule J, part II. A COLORADO HEALTH FACILITIES AUTHORITY REV 840752932 000000000 2010-12-29 22881000 Refund 2006 & 2007 Bonds, Finance New Administration Building false false false B COLORADO HEALTH FACILITIES AUTHORITY REV 840752932 000000000 2015-02-12 9108000 FUNDING FOR FACILITY EXPANSION false false false A 14097000 22881000 247691 6800729 15832580 2012 true false true true B 4276183 9108000 50001 9057999 2015 false false true true A false false false false 0.0 0.0 0.0 false false true B false false false false 0.0 false false true A false false false true true false false false true B false false true false false false false false true A true B true Schedule K, Part I BOND ISSUES AN AGREEMENT WAS PUT IN PLACE WITH THE ISSUER AT THE TIME THE BONDS WERE ISSUED WITH RESPECT TO PERMITTED USE OF BOND-FINANCED ASSETS AND REMEDIAL ACTIONS UNDER TREAS. REG. SS 1.145-2(A) AND 1.14112) THAT WILL BE UNDERTAKEN IF THERE IS AN IMPERMISSIBLE CHANGE IN USE OF SUCH ASSETS. ADDITIONALLY, THE ALLOSOURCE BOARD OF DIRECTORS HAS ADOPTED A RESOLUTION EFFECTIVE JULY 31, 2012, ESTABLISHING PROCEDURES TO ENSURE ANY VIOLATIONS THAT CANNOT BE "SELF-CORRECTED" UNDER TREAS. REG. SS 1.141(12) WILL BE REMEDIATED THROUGH THE IRS'S VOLUNTARY CLOSING AGREEMENT PROGRAM AS DESCRIBED IN NOTICE 2008-31. Schedule K, Part IV, Line 2c Column A The 2010 Issue was Reissued on 3/21/2012. The 2012 reissue met the exception to rebate. Schedule K, Part IV, Line 2c COLUMN A Issuer name: COLORADO HEALTH FACILITIES AUTHORITY REV The calculation for computing no rebate due was performed on 03/21/2012 Form 990, Part VI, Line 6 Classes of members or stockholders THE ORGANIZATION HAS ONE CLASS OF MEMBERSHIP. EACH CORPORATE MEMBER IS A 501 (c)(3), TAX EXEMPT ORGANIZATION. Form 990, Part VI, Line 7a Members or stockholders electing members of governing body EACH CORPORATE MEMBER HAS THE EXECUTIVE POWER TO ELECT AND REMOVE, WITH OR WITHOUT CAUSE, ONE OF THE VOTING DIRECTORS OF THE CORPORATION, EXCLUDING EX-OFFICIO VOTING DIRECTORS. Form 990, Part VI, Line 8b Documentation of meetings held by committees of governing body THE ORGANIZATION DOES NOT HAVE ANY COMMITTEES WITH AUTHORITY TO ACT ON BEHALF OF THE GOVERNING BODY. Form 990, Part VI, Line 11b Review of form 990 by governing body THE FORM 990 IS REVIEWED BY THE ORGANIZATION'S KEY OFFICERS AND CHIEF LEGAL OFFICER FOR BOTH DESCRIPTION AND NUMERIC CONTENT. THE FORM IS THEN REVIEWED BY OUTSIDE COUNSEL. AFTER THESE REVIEWS, THE FORM IS SENT TO THE AUDIT COMMITTEE FOR A DETAILED REVIEW AND OPPORTUNITY TO PROVIDE COMMENTS AND RECOMMENDATIONS TO MANAGEMENT. SUBSEQUENT TO INCORPORATION OF THE AUDIT COMMITTEE RECOMMENDATION INTO THE FORM 990, THE COMMITTEE ADOPTS A RESOLUTION TO RECOMMEND THE FORM 990 TO THE BOARD, AT WHICH TIME THE FORM 990 IS SUBMITTED TO THE BOARD FOR REVIEW AND ACCEPTANCE. Form 990, Part VI, Line 12c Conflict of interest policy THE ORGANIZATION MONITORS THE POLICY BY REVIEWING THE ANNUAL CONFLICT OF INTEREST POLICY STATEMENTS RECEIVED FROM ITS DIRECTORS, OFFICERS AND KEY EMPLOYEES IN ACCORDANCE WITH THE ORGANIZATION'S CONFLICT OF INTEREST POLICY. IN CONNECTION WITH ANY ACTUAL OR POTENTIAL CONFLICT OF INTEREST, AN INTERESTED PERSON IMMEDIATELY MUST DISCLOSE IN WRITING OR AT A NOTICED MEETING OF THE BOARD OF DIRECTORS THE EXISTENCE AND NATURE OF THE CONFLICT AND OF HIS OR HER FINANCIAL INTEREST TO THE BOARD OF DIRECTORS. IN ALL EVENTS, SUCH WRITTEN DISCLOSURE MUST BE MADE IN SUFFICIENT TIME TO PERMIT THE BOARD, WHILE CONSIDERING THE PERTINENT ALLOSOURCE BUSINESS ACTIVITY, TO CONSIDER THE DISCLOSURE, MAKE NECESSARY OR APPROPRIATE INQUIRY, AND TAKE SUITABLE ACTION IN RESPECT TO AND IN LIGHT OF THE DISCLOSURE. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS. AFTER DISCLOSURE OF THE ACTUAL OR POTENTIAL CONFLICT OF INTEREST IN FULL DETAIL, THE INTERESTED PERSON SHALL LEAVE THE BOARD MEETING WHILE THE QUESTION OF THE EXISTENCE AND MATERIALITY OF THE DISCLOSED CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON BY THE REMAINING BOARD MEMBERS PRESENT AT THE MEETING. NO SUCH DEPARTURE BY A DISCLOSING INTERESTED PERSON SHALL DEFEAT THE EXISTENCE OF A QUORUM TO CONDUCT THE BUSINESS UNDER CONSIDERATION. THE REMAINING BOARD MEMBERS SHALL DECIDE BY MAJORITY VOTE, UNLESS OTHERWISE PRESCRIBED BY THE BYLAWS, WHETHER A CONFLICT OF INTERST EXISTS AND, IF A CONFLICT DOES EXIST, WHETHER IT IS MATERIAL AND THEREFORE IMPERMISSIBLE CONDUCT FOR THE DISCLOSING INTERESTED PERSON. THE CHAIRPERSON OF THE BOARD OF DIRECTORS SHALL, IN HIS OR HER DISCRETION APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE THE IMPACT OF THE DISCLOSED CONFLICT IN THE CONTEXT OF THE PROPOSED TRANSACTION, ARRANGEMENT, BUSINESS RELATIONSHIP, OR CONTRACT. AFTER EXERCISING DUE DILIGENCE IN SUCH INVESTIGATION, THE BOARD SHALL DETERMINE WHETHER ALLOSOURCE MAY ACHIEVE A MORE ADVANTAGEOUS TRANSACTION, ARRANGEMENT, BUSINESS RELATIONSHIP, OR CONTRACT WITH REASONABLE EFFORT, FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. IF A MORE ADVANTAGEOUS TRANSACTION, ARRANGEMENT BUSINESS RELATIONSHIP, OR CONTRACT MAY NOT REASONABLY BE ACHIEVED UNDER CIRCUMSTANCES WHICH WOULD AVOID THE CONFLICT OF INTEREST, THE BOARD SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION, ARRANGEMENT, BUSINESS RELATIONSHIP, OR CONTRACT IS IN ALLOSOURCE'S BEST INTEREST AND WHETHER THE RESULT IS FAIR AND REASONABLE TO ALLOSOURCE, NOTWITHSTANDING THE CONFLICT OF INTEREST. THE BOARD ALSO SHALL EVALUATE THE POSSIBLE APPEARANCE OF IMPROPRIETY AND POTENTIAL FOR ADVERSE IMPACT ON DONATION IN ITS DELIBERATIONS. THE BOARD SHALL BE GUIDED IN ITS DECISION BY THE PRINCIPLES ARTICULATED ABOVE. IF THE BOARD HAS REASONABLE CAUSE TO BELIEVE THAT AN INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST, IT SHALL INFORM THE INTERESTED PERSON OF THE BASIS FOR THE BOARD'S BELIEF AND AFFORD THE INTERESTED PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. IF, AFTER HEARING THE RESPONSE FROM THE INTERESTED PERSON AND MAKING SUCH FURTHER INVESTIGATION AS THE BOARD MAY WISH THE BOARD DETERMINES THAT THE INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST, THE BOARD SHALL TAKE ANY DISCIPLINARY AND CORRECTIVE ACTION IT DEEMS APPROPRIATE, INCLUDING RECOMMENDATION TO THE CORPORATE MEMBER THAT THE INTERESTED PERSON, IF A DIRECTOR OF ALLOSOURCE, BE REMOVED OR EXPELLED BY FURTHER ACTION OF THE PERTINENT CORPORATE MEMBER PURSUANT TO THE ALLOSOURCE BYLAWS, EXPULSION OF AN INTERESTED PERSON OTHER THAN A DIRECTOR, AND PURSUIT OF A CLAIM FOR RESTITUTION OR DAMAGES, AS THE BOARD MAY DECIDE. Form 990, Part VI, Line 15a Process to establish compensation of top management official THE PROCESS FOR SETTING COMPENSATION FOR THE CEO BEGINS BY ESTABLISHING GOALS AND OBJECTIVES EACH YEAR. THE BOARD OF DIRECTORS EVALUATES THIS POSITION'S PERFORMANCE TO THE GOALS AND OBJECTIVES FOR PERFORMANCE EVALUATIONS. THE CEO'S PERFORMANCE, ALONG WITH BENCHMARK DATA SUPPLIED FROM A THIRD-PARTY ON COMPARABLE SALARIES AND BENEFIT PACKAGES, ARE UTILIZED TO ARRIVE AT THE CEO'S COMPENSATION. THIS PROCESS AND A REASONABLENESS REVIEW CONDUCTED BY THE BOARD OF DIRECTORS WAS LAST COMPLETED IN 2022. Form 990, Part VI, Line 15b Process to establish compensation of other employees FOR BOTH THE CHIEF FINANCIAL OFFICER AND CHIEF LEGAL OFFICER, THE PERFORMANCE ALONG WITH BENCHMARK DATA SUPPLIED FROM A THIRD-PARTY ON COMPARABLE SALARIES AND BENEFIT PACKAGES, ARE UTILIZED TO ARRIVE AT THEIR COMPENSATION. THIS PROCESS AND A REASONABLENESS REVIEW CONDUCTED BY THE BOARD OF DIRECTORS WAS LAST COMPLETED IN 2022. Form 990, Part VI, Line 19 Required documents available to the public THE GOVERNING DOCUMENTS ARE MADE AVAILABLE FOR PUBLIC INSPECTION AT THE ORGANIZATION'S OFFICE IN CENTENNIAL, COLORADO, ALONG WITH THE ORGANIZATION'S EXEMPTION APPLICATION, FORM 1023. THE CONFLICT OF INTEREST POLICY IS NOT MADE AVAILABLE FOR PUBLIC INSPECTION. THE FINANCIAL STATEMENTS ARE AUDITED BY INDEPENDENT ACCOUNTANTS. THE FINANCIAL STATEMENTS INCLUDE THE STATEMENT OF REVENUE AND EXPENSES AND BALANCE SHEET, AND ARE REPORTED ON THE ORGANIZATION'S FORM 990 IN PARTS VIII, IX, AND X, AND SCHEDULE D. THE FORM 990 AND SCHEDULES ARE MADE AVAILABLE UPON REQUEST AT THE OFFICE OF THE ORGANIZATION IN CENTENNIAL, COLORADO. Form 990, Part XI, Line 9 Other changes in net assets or fund balances LOSS ON DISPOSAL OF FIXED ASSETS BEFORE BEING FULLY DEPRECIATED - -172753; ESSENT BIOLOGICS LLC 6278 S TROY CIR CENTENNIAL CO 80111 843601661 PROCESS & DEVELOP HUMAN TISSUE DE -3142994 1206305 ALLOSOURCE